We’re all about humanity
We make a difference in the lives of patients around the world with serious and rare diseases because the vitality of our science is powered by our core values.
A global commitment
Our commitment to patients has no borders. In addition to our global corporate headquarters in Bridgewater, NJ, we have offices throughout Europe and in Japan, with more than 600 employees who are dedicated to serving the needs of patients and their families. We continue to build our global infrastructure and organizational capabilities as we pursue regulatory approvals in multiple regions.
Our company has evolved significantly over the years, but our commitment to patients remains. As we look toward the future, we are inspired by our vision to deliver life-altering therapies to small patient populations experiencing big health problems.
Our key milestones
Insmed announces positive topline results from its Phase 3 ARISE study.
Insmed completes enrollment of adult patients in its Phase 3 ASPEN study.
Insmed announces strategic financings that will enable the Company to deliver clinical data from each of its four pillars.
Insmed holds its inaugural Global Day of Good, a company-wide day of service to support the communities where employees live and work.
Insmed is re-certified as a Great Place to Work in the U.S. and ranks No. 1 on Science magazine’s Top Biopharma Employers List for the second year in a row. The Company also ranks No. 90 on the Deloitte Technology Fast 500 List, North America.
Insmed establishes new Research facilities in New Hampshire and San Diego to support the evolution of its fourth pillar.
Insmed’s first product is approved and launches in Japan.
Insmed reports positive Phase 1 data for its earlier-stage product candidate in healthy volunteers.
Insmed initiates clinical program to evaluate first approved product in the frontline setting.
Insmed’s first product is approved in Europe; initial country launches begin.
Insmed reports positive data for its Phase 2 product candidate and announces plans to advance to Phase 3 development.
Insmed opens its new, state-of-the-art global headquarters in Bridgewater, NJ, to support the Company’s continued growth.
Insmed is granted accelerated approval by the FDA for its first therapy.
Insmed submits a New Drug Application to the FDA for its lead product candidate.
Insmed establishes a subsidiary in Japan.
Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline.
Insmed opens an office in Utrecht, Netherlands, further expanding its presence to Europe.
Insmed receives Orphan Drug Designation, Qualified Infectious Disease Product designation, and Fast Track status for its lead product candidate.
Insmed enters into a business combination with Transave, acquiring its late-stage candidate. The new company maintains the name Insmed.
Transave pioneers the early development of an inhaled liposomal antibiotic, an advancement that will later enable the approval of the Company’s first therapy.
Insmed is incorporated in the Commonwealth of Virginia and becomes a public company (INSM) after acquiring Celtrix Pharmaceuticals in a reverse merger.
Transave is founded as a private company by Dr. Frank Pilkiewicz in Monmouth Junction, NJ, to develop inhaled pharmaceuticals for the treatment of lung diseases.
Insmed is founded as a private company by Dr. Joseph Larner in Charlottesville, Va., to develop medicines to treat diabetes.
An installation at Insmed’s global headquarters honors the Company’s past as we look toward the future. From the early days of the two original companies that formed Insmed to the FDA approval and launch of our first therapy, the wall highlights some of the most significant moments in Insmed’s history and showcases the values that we live every day.